Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on September 4, 2008, to announce the results of a Phase 2 study for its drug ARCALYST® (rilonacept). The study evaluated the efficacy and safety of ARCALYST® in preventing gout flares when initiating uric acid-lowering therapy for gout management. This filing includes a press release detailing the study's findings and slides from a webcast discussion hosted by Regeneron's senior management. These documents provide crucial information for investors regarding the progress and potential of ARCALYST® in a specific therapeutic area, highlighting the company's ongoing research and development efforts.
Key Highlights
- 1Regeneron announced the release of Phase 2 study results for ARCALYST® (rilonacept).
- 2The study focused on preventing gout flares associated with the initiation of gout treatment.
- 3ARCALYST® was evaluated against a placebo.
- 4The filing includes a press release detailing the study findings.
- 5Webcast slides discussing the study results are also provided.
- 6This event underscores Regeneron's commitment to advancing its pipeline, specifically in the treatment of gout.
Frequently Asked Questions
ARCALYST® (rilonacept) is being studied for its efficacy and safety in preventing gout flares that can occur when patients begin treatment with uric acid-lowering drugs to manage gout.
The study reported in this 8-K is a Phase 2 study.
This 8-K filing includes a press release (Exhibit 99(a)) announcing the Phase 2 study results and slides (Exhibit 99(b)) from a webcast where Regeneron's management discussed these findings.
The primary objective was to evaluate the efficacy and safety of ARCALYST® in preventing gout flares induced by the initiation of uric acid-lowering drug therapy.